Therapeutic Drug Monitoring of Tacrolimus Biliary Concentrations for Liver-transplanted Patients (STABILE)

• Status: Completed
• Trial end date: 2017-04-07
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to demonstrate that the biliary concentration of TCR is a good marker of its immunosuppressive activity.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rennes University Hospital
• Treatments: Tacrolimus

Criteria

Inclusion Criteria:

• Adult patients (> 18 years) of both sexes,

• Candidates for liver transplantation or retransplantation, whatever the etiology and severity of the underlying disease,

• Not having expressed their opposition to participation in the study

Exclusion Criteria:

• Bilio-enteric anastomosis,

• Associated transplantation of another organ

• Contraindications to TCR administration

• Delayed introduction of TCR (beyond the 5th postoperative day) whatever the cause.